SEARCH

SEARCH BY CITATION

References

  • 1
    Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J 1982; 284: 706.
  • 2
    Somerville KW, Logan REA, Edmond M, et al. Smoking and Crohn's disease. Br Med J 1984; 289: 9546.
  • 3
    Lofberg R. Medical treatment of mild to moderate active Crohn's disease. Alim Pharmacol Ther 2003; 17(Suppl. 2): 1822.
  • 4
    Shields PL, Low-Beer TS. Patient's awareness of adverse relation between Crohn's disease and their smoking: questionnaire survey. BMJ 1996; 313: 2656.
  • 5
    USDHHS. Treating Tobacco Use and Dependence. Rockville, MD: Agency for Healthcare Research Quality, 2000.
  • 6
    Forbes A. Smoking and inflammatory bowel disease. European J Gastroenterology & Hepatology 1996; 8: 7613.
  • 7
    Thomas GAO, Rhodes J, Green JT. Inflammatory bowel disease and smoking – a review. Am J Gastroenterology 1998; 93: 1449.
  • 8
    Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci 1989; 34: 184154.
  • 9
    Lee JCW, Lennard-Jones JE. Inflammatory bowel disease in 67 families each with three or more affected first-degree relatives. Gastroenterology 1996; 111: 58796.
  • 10
    Bridger S, Lee JCW, Bjarnason I, et al. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis. Gut 2002; 51: 215.
  • 11
    Mokbel M, Carbonnel F, Beaugerie L, et al. Effect of smoking on the long term course of ulcerative colitis. Gastroenterol Clin Biol 1998; 22: 85862.
  • 12
    Beaugerie L, Massot N, Carbonnel F, et al. Impact of cessation of smoking on the course of ulcerative colitis. Am J Gastroenterol 2001; 96: 21136.
    Direct Link:
  • 13
    Bokyo EJ, Perera DR, Koepsell TD, et al. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol 1988; 23: 114752.
  • 14
    Palli D, Trallori G, Saieva C. General and cancer specific mortality of a population based cohort of patients with inflammatory bowel disease: the Florence Study. Gut 1998; 42: 1759.
  • 15
    Ekbom A, Helmick CG, Zack M, et al. Survival and causes of death in patients with inflammatory bowel disease: a population based study. Gastroenterology 1992; 103: 95460.
  • 16
    Sutherland LR, Ramcharan S, Bryant H, et al. Effect of cigarette smoking on recurrence of Crohn's disease. Gastroenterology 1990; 98: 11238.
  • 17
    Breuer-Katchinski BD, Hollander N, Goebell H. Cigarette smoking on the course of Crohn's disease. European J Gastroenterology & Hepatology 1996; 8: 2258.
  • 18
    Cosnes J, Carbonnel F, Beaugerie L, et al. Effects of cigarette smoking on the long term course of Crohn's disease. Gastroenterology 1996; 110: 42431.
  • 19
    Lindberg E, Jamerot G, Huitfeldt B. Smoking in Crohn's disease: effect on localisation and clinical course. Gut 1992; 33: 77982.
  • 20
    Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn's disease. Gastroenterology 1994: 106: 6438.
  • 21
    Cosnes J, Carbonnel F, Carrat F, et al. Respective effects of current and former cigarette smoking on the clinical course of Crohn's disease. Alim Pharmacol Ther 1999; 13: 140311.
  • 22
    Cosnes J, Nion-Larmurier I, Afchain P, et al. Gender differences in the response of colitis to smoking. Clin Gastroenterol Hepatol 2004; 2: 418.
  • 23
    Cosnes J, Carbonnel F, Carrat F, et al. Oral contraceptives and the clinical course of Crohn's disease: a prospective cohort study. Gut 1999; 45: 21822.
  • 24
    Zeman MV, Hiraki L, Sellers EM. Gender differences in tobacco smoking: higher relative exposure to smoke than nicotine in women. J Women's Health and Gender Based Med 2002; 11: 14753.
  • 25
    Rider V, Abdou NI. Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. Int J Immunopharmacol 2001; 1: 100924.
  • 26
    Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the clinical course of Crohn's disease: an intervention study. Gastroenterology 2001; 120: 10939.
  • 27
    Pearson DC, May GR, Fick G, et al. Azathioprine for Maintenance of Remission in Crohn's disease (Cochrane Review), Issue 3. Oxford: Update Software, The Cochrane Library, 2003.
  • 28
    Arnott IDR, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 14517.
  • 29
    Sopori M. Effects of cigarette smoke on the immune system. Nature reviews. Immunology 2002; 2: 3727.
  • 30
    Wang H, Yu M, Ochani M, et al. Nicotinic acetlycholine receptor α7 subunit is an essential regulator of inflammation. Nature 2003; 421: 3848.
  • 31
    Moore B, Otterbein LE, Türler A, et al. Inhaled carbon monoxide suppresses the development of postoperative ileus in the murine small intestine. Gastroenterology 2003; 124: 37791.
  • 32
    Finnie IA, Campbell BJ, Taylor BA, et al. Stimulation of colonic mucin synthesis by corticosteroids and nicotine. Clin Sci (London) 1996; 91: 35964.
  • 33
    Louvet B, Buisine MP, Desreumaux P, et al. Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. Inflamm Bowel Dis 1999; 5: 17481.
  • 34
    Hatoum OA, Binion DG, Otterson MF, et al. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilatation. Gastroenterology 2003; 125: 5869.
  • 35
    Genser D, Kang MH, Vogelsang H, et al. Status of lipid soluble antioxidants and TRAP in patients with Crohn's disease and healthy controls. Eur J Clin Nutr 1999; 53: 6759.
  • 36
    Wakefield AJ, Sawyerr AM, Dhillon AP, et al. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet 1989; 2: 105762.
  • 37
    Lancaster T, Stead LF. Physician advice for smoking cessation. The Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD000165.pub2. DOI: 10.1002/14651858.CD000165.pub2.
  • 38
    Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. The Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD000146.pub2. DOI: 10.1002.14651858.CD000146.pub2.
  • 39
    Lancaster T, Silagy C, Fowler G. Training health professionals in smoking cessation. The Cochrane Database of Systematic Reviews 2000, Issue 3. Art. No.: CD000214. DOI: 10.1002/1465.1858.CD000214.
  • 40
    Hajek P, Stead LF. Aversive smoking for smoking cessation. The Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD000546.pub2. DOI: 10.1002/14651858.CD000546.pub2.
  • 41
    White AR, Rampes H, Ernst E. Acupuncture for smoking cessation. The Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD000009. DOI: 10.1002/14651858.CD00009.
  • 42
    Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. The Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD000058.pub2. DOI: 10.1002/14651858.CD000058.pub2.
  • 43
    Stead LF, Hughes HR. Lobeline for smoking cessation. The Cochrane Database of Systematic Reviews 1997, Issue 3. Art. No.: CD000124. DOI: 10.1002/14651858.CD000124.
  • 44
    Hughes JR, Stead LF, Lancaster T. Anxiolytics for smoking cessation. The Cochrane Database of Systematic Reviews2000, Issue 4. Art. No.: CD002849. DOI: 10.1002/14651858.CD002849.
  • 45
    Lancaster T, Stead LF. Silver acetate for smoking cessation. The Cochrane Database of Systematic Reviews 1997, Issue 3. Art. No.: CD000191. DOI@ 10.1002/14651858.CD000191.
  • 46
    Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. The Cochrane Database of Systematic Reviews 1998, issue 2. Art. No.: CD001009. DOI: 10.1002/14651858.CD001009.
  • 47
    Abbot NC, Stead LF, White AR, Barnes J. Hypnotherapy for smoking cessation. The Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No.: CD001008. DOI: 10.1002/14651858.CD001008.
  • 48
    Raw R, McNeill A, West R. Smoking cessation guidelines for the health professionals: A guide to effective smoking cessation interventions for the health care system. Thorax 1998; 53(Suppl. 5): S1S18.
  • 49
    West R, McNeill A, Raw M. Smoking cessation guidelines for the health professionals: an update. Thorax 2000; 55: 98799.
  • 50
    Fiore M, Bailey W, Cohen SJ, et al. Smoking Cessation Clinical Practice, guideline no. 18. Rockville: Agency for health care policy and research, US Department of Health and Human Services, 1996.
  • 51
    Raw M, McNeill A, West R. Smoking cessation: evidence based recommendations for the healthcare system. Br Med J 1999; 318: 1825.
  • 52
    Edwards R. The problem of tobacco smoking. Br Med J 2004; 328: 2179.
  • 53
    Jarvis M. Why people smoke. Br Med J 2004; 328: 2779.
  • 54
    West R. Assessment of dependence and motivation to stop smoking. Br Med J 2004: 328: 3389.
  • 55
    Coleman T. Use of simple advice and behavioural support. Br Med J 2004; 328: 3979.
  • 56
    Molyneux A. Nicotine replacement therapy. Br Med J 2004; 328: 4546.
  • 57
    Roddy E. Bupropion and other non-nicotine pharmacotherapies. Br Med J 2004; 328: 50911.
  • 58
    Coleman T. Special groups of smokers. Br Med J 2004; 328: 5757.
  • 59
    Coleman T. Cessation interventions in routine health care. Br Med J 2004; 328: 6313.
  • 60
    Spice P. Setting up a cessation service. Br Med J 2004; 328: 699701.
  • 61
    Jamrozik K. Population strategies to prevent smoking. Br Med J 2004; 328: 75962.
  • 62
    A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. JAMA 2000: 283; 324454.
  • 63
    Yudkin P, Hey K, Roberts S, et al. Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. Br Med J 2003: 327: 289.
  • 64
    Silagy C. Physician advice for smoking cessation. Cochrane Database Syst review 2000; 2: CD000165.
  • 65
    Russell MA, Wilson C, Taylor C, et al. Effect of general practitioners’ advice against smoking. BMJ 1979; 2: 2315.
  • 66
    Senore C, Battista RN, Shapiro SH, et al. Predictors of smoking cessation following physicians’ counselling. Prev Med 1998; 27: 41221.
  • 67
    Butler CC, Pill R, Scott NC. Qualitative study of patients’ perceptions of doctors’ advice to quit smoking: implications for opportunistic health promotion. Br Med J 1998; 316: 187881.
  • 68
    Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2000; 2: CD001292.
  • 69
    Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline in FEV1. The Lung Health Study. JAMA 1994; 272: 1497505.
  • 70
    McGuire TA, McElnay JC, Drummond A. A randomised controlled trial of smoking cessation intervention based in community pharmacies. Addiction 2001: 96: 48594.
  • 71
    Rice VH, Stead LF. Nursing interventions for smoking cessation. Cochrane database Syst Rev 2000; 2: CD001188.
  • 72
    Steptoe A, Doherty S, Rink E, et al. Behavioural counselling in general practice for the promotion of healthy behaviour among adults at increased risk of coronary heart disease: randomised trial. Br Med J 1999: 319: 9437.
  • 73
    Moolchan ET, Ernst M, Henningfield JE. A review of tobacco smoking in adolescents: treatment implications. J Am Acad Child Adolesc Psychiatry 2000; 39: 68293.
  • 74
    Zhu SH, Stretch V, Balabanis M, et al. Telephone counselling for smoking cessation: effects of single-session and multiple session interventions. J Consult Clin Psychol 1996; 64: 20211.
  • 75
    Lancaster T, Stead LF. Self help interventions for smoking cessation. Cochrane database Syst Rev 2000; 2: CD001118.
  • 76
    Nicotine replacement therapy to aid smoking cessation. Drug Ther Bull 1999; 37: 524.
  • 77
    Hays JT, Croghan IT, Schroeder DR, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomised, double blind, placebo controlled, and open blind trials. Am J Public Health 1999; 89: 17017.
  • 78
    Davidson M, Epstein M, Burt R, et al. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid to smoking cessation. Arch Fam Med 1998; 7: 56974.
  • 79
    Hajek P, West R, Foulds J, et al. Randomised comparative trial of nicotine polacrilex, a transdermal patch, nasal spray and an inhaler. Arch Intern Med 1999; 159: 20338.
  • 80
    Silagy C, Mant D, Fowler G, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2000; 2: CD000146.
  • 81
    Daughton DM, Fortmann SP, Glover ED, et al. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to years post-quit day. Prev Med 1999; 28: 1138.
  • 82
    Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997; 337: 1195202.
  • 83
    Jorenby DE, Leischow SJ, Nides Ma, et al. A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340: 68591.
  • 84
    Kast RE, Altschuler EL. Remission of Crohn's disease on bupropion. Gastroenterology 2001; 121: 12601.
  • 85
    Gonzales D, Bjornson W, Durcan MJ, et al. Effects of gender on relapse prevention in smokers treated with bupropion SR. Am J Prev Med 2002; 22: 2349.
  • 86
    Prochazka AV, Weaver MJ, Keller RT, et al. A randomised trial of nortriptyline for smoking cessation. Arch Intern Med 1998; 158: 20359.
  • 87
    Hall SM, Reus VI, Munoz RF, et al. Nortriptyline and cognitive-behavioural therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 1998; 55: 68390.